ACHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ACHC is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who is impatient and wants to deploy capital immediately. The stock has fundamental improvement and strong analyst upgrades, but the current chart is weak, sentiment is mixed, hedge funds are selling, and the latest guidance disappointed the market. I would not buy aggressively at this level; holding off is the better call.
The trend is weak to bearish. Price closed at 24.48, below the pivot of 26.194 and near the first support at 22.909. MACD histogram is -0.51 and still expanding negatively, which confirms downside momentum. RSI_6 is around 29.95, showing an oversold condition, but not a confirmed reversal. Moving averages are converging, so a trend change is possible, but there is no clear bullish breakout yet. The near-term stock trend model also points to downside pressure over the next day, week, and month.
Management commentary reportedly softened earlier concerns around broad-based denial and bad debt issues. There is also optimism from the reappointment of former CEO Debra K. Osteen.
The stock fell 9% after Q2 revenue guidance of $842.5 million came in below expectations. Net income dropped 50.98% YoY and EPS fell 44.44% YoY in the latest quarter, showing weaker profitability despite revenue growth. Hedge funds have been selling aggressively, with selling up 194.77% over the last quarter. Cantor Fitzgerald remains Neutral and flagged ongoing bad debt and denial trends. The price action and modeled short-term trend both lean negative.
In Q1 2026, Acadia delivered revenue of $828.8 million, up 7.57% YoY, which shows solid top-line growth. But profitability weakened sharply, with net income down to $4.1 million, a 50.98% YoY decline, and EPS down 44.44% YoY to $0.05. This means the latest quarter season was a revenue beat but a profit-quality concern. For a long-term beginner investor, the growth is encouraging, but the earnings deterioration makes the current setup less attractive.
Analyst sentiment has improved meaningfully in the last two weeks. Multiple firms raised price targets: RBC to $31, Guggenheim to $31, Deutsche Bank to $32, TD Cowen to $30, UBS to $31, and Raymond James to $39 with a Strong Buy upgrade. However, not all of Wall Street is bullish: Barclays remains Equal Weight, Jefferies is Hold, and Cantor Fitzgerald is Neutral. Overall, the pros see valuation upside and operating execution, while the cautious camp still worries about bad debt, denial trends, and near-term volume stability.
